Sarepta (SPRT): FDA Request for Dystrophin Data a 'Clear Indication Willing to Grant Accelerated Approval' - Baird

Baird analyst Brian Skorney reiterated an Outperform rating and $23 price target on Sarepta Therapeutic (NASDAQ: SRPT), saying the FDA's request for dystrophin analysis is a positive for SRPT shares.

"We believe it signals a clear indication that the agency is willing to grant eteplirsen ‎accelerated approval, provided the expression of dystrophin in the biopsied samples from the PROMOVI study is consistent with the results of Study 201/202," Skorney said.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $16.05 yesterday.

You May Also Be Interested In

• Barclays Starts Cranswick Plc. (CWK:LN) at Overweight
• Goldman Sachs Downgrades Ferguson Plc. (FERG) to Neutral, 'We now see better opportunities elsewhere in our coverage'
• Terawulf Inc. (WULF) PT Raised to $40 at Compass Point